TSHA

Taysha Gene Therapies Inc

Feb 06 • 04:00PM ET

4.61

+0.20 4.54 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT CRSP NTLA BLUE QURE EDIT IOVA ADVM SGMO GNFT

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA FESM IWC

Index	RUT	P/E	-	EPS (ttm)	-0.35	Insider Own	20.14%	Shs Outstand	273.92M	Perf Week	2.22%
Market Cap	1.26B	Forward P/E	-	EPS next Y	-0.43	Insider Trans	-2.27%	Shs Float	218.75M	Perf Month	-13.18%
Enterprise Value	1.03B	PEG	-	EPS next Q	-0.09	Inst Own	90.62%	Short Float	25.99%	Perf Quarter	14.39%
Income	-99.93M	P/S	200.12	EPS this Y	-0.40%	Inst Trans	3.10%	Short Ratio	17.81	Perf Half Y	64.06%
Sales	6.31M	P/B	5.77	EPS next Y	-18.96%	ROA	-40.23%	Short Interest	56.85M	Perf YTD	-16.18%
Book/sh	0.80	P/C	4.24	EPS next 5Y	-10.32%	ROE	-64.93%	52W High	6.02 -23.42%	Perf Year	172.78%
Cash/sh	1.09	P/FCF	-	EPS past 3/5Y	57.45% -63.99%	ROIC	-34.89%	52W Low	1.05 339.05%	Perf 3Y	280.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	81.77%	Volatility	5.43% 6.30%	Perf 5Y	-82.31%
Dividend TTM	-	EV/Sales	163.94	EPS Y/Y TTM	-945.72%	Oper. Margin	-1618.54%	ATR (14)	0.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.47	Sales Y/Y TTM	-36.36%	Profit Margin	-1583.66%	RSI (14)	45.41	Recom	1.07
Dividend Gr. 3/5Y	- -	Current Ratio	10.47	EPS Q/Q	2.83%	SMA20	-2.32%	Beta	1.01	Target Price	11.00
Payout	-	Debt/Eq	0.32	Sales Q/Q	-100.00%	SMA50	-9.06%	Rel Volume	0.83	Prev Close	4.41
Employees	73	LT Debt/Eq	0.31	Earnings	Nov 04 BMO	SMA200	26.71%	Avg Volume	3.19M	Price	4.61
IPO	Sep 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.01% -80.03%	Trades		Volume	2,636,350	Change	4.54%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Raymond James	Strong Buy	$13
Jul-11-25	Initiated	BofA Securities	Buy	$8
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$5
Apr-09-24	Initiated	Piper Sandler	Overweight	$9
Feb-01-23	Downgrade	Jefferies	Buy → Hold	$14 → $1.50
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$23 → $3
Nov-09-22	Downgrade	Goldman	Buy → Neutral	$16 → $3
Mar-09-22	Initiated	Robert W. Baird	Outperform	$26
Mar-01-22	Initiated	Wells Fargo	Overweight	$25
Feb-18-22	Initiated	SMBC Nikko	Outperform	$25
Dec-16-21	Initiated	Guggenheim	Buy	$28
Jul-16-21	Initiated	Needham	Buy	$45
Jun-24-21	Initiated	Truist	Buy	$60
Jun-15-21	Initiated	BTIG Research	Buy	$44
Jun-09-21	Initiated	Wedbush	Outperform	$31
Jun-08-21	Initiated	JMP Securities	Mkt Outperform	$40
May-19-21	Initiated	Cantor Fitzgerald	Overweight	$44
May-11-21	Resumed	Jefferies	Buy	$34 → $45
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform	$42

Show Previous Ratings

Today 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-26 09:37AM	Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress (Insider Monkey)
Jan-29-26 01:48PM	Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA) (Insider Monkey)
Jan-14-26 02:13PM	Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects (Insider Monkey)
Jan-06-26 08:00AM	Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome (GlobeNewswire) +7.57%
07:31AM	Loading…
Dec-21-25 07:31AM	Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program (Insider Monkey)
Dec-05-25 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.92%
Nov-18-25 06:17AM	Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? (Insider Monkey)
Nov-07-25 09:34PM	Citizens Lifts Price Target for Taysha Gene Therapies (TSHA) (Insider Monkey)
Nov-04-25 04:09PM	Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) -5.62%
07:00AM	Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-25 07:41AM	What To Expect From Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings (GuruFocus.com) -10.08%
Oct-28-25 08:00AM	Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 (GlobeNewswire)
Oct-26-25 06:16AM	Raymond James Initiates Strong Buy on Taysha (TSHA) Amid Rett Syndrome Trial Momentum (Insider Monkey)
Oct-17-25 06:00AM	I-Mab morphs into hub-and-spoke biotech; Astellas passes on Taysha gene therapy (BioPharma Dive) -7.09%
03:14AM	Loading…
03:14AM	Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last? (Zacks)
Oct-16-25 04:01PM	Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome (GlobeNewswire)
Oct-09-25 08:00AM	Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting (GlobeNewswire)
Oct-03-25 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Oct-02-25 08:00AM	Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome (GlobeNewswire) +53.46%
Sep-05-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-25 11:56PM	Piper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9 (Insider Monkey)
Aug-13-25 03:07AM	Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ... (GuruFocus.com)
Aug-12-25 03:00PM	Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +5.43%
08:01AM	Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:27AM	Earnings To Watch: Taysha Gene Therapies Inc (TSHA) Reports Q2 2025 Result (GuruFocus.com)
Aug-07-25 05:15PM	Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates (Zacks)
Aug-05-25 04:05PM	Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 (GlobeNewswire)
Aug-04-25 10:01AM	Wells Fargo Remains Bullish on Taysha Gene Therapies (TSHA) (Insider Monkey)
10:00AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know (Zacks)
05:06PM	Loading…
Aug-01-25 05:06PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
06:47AM	BofA Securities Affirms 'Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects (Insider Monkey)
Jul-22-25 06:54AM	Leigh Syndrome Market Research Report 2025-2035 \| Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics (GlobeNewswire)
Jul-16-25 12:00PM	Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jul-03-25 01:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:08AM	Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Jun-24-25 03:51PM	Jefferies Maintains a Buy on Taysha Gene Therapies (TSHA) With an $8 PT (Insider Monkey)
Jun-18-25 09:16AM	Craig-Hallum bullish on Neurogene, initiates with a Buy (TipRanks)
Jun-06-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-25 05:17PM	Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program (GlobeNewswire)
May-29-25 12:12AM	Taysha Gene Therapies, Inc. (TSHA)'s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+ (Insider Monkey) +12.70%
May-28-25 10:40PM	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -6.33%
04:02PM	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102 (GlobeNewswire)
May-16-25 03:19AM	Q1 2025 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents) +5.47%
03:09AM	Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ... (GuruFocus.com)
May-15-25 09:10AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.02%
08:00AM	Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-14-25 09:40AM	Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:40PM	Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.53%
04:05PM	Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15 (GlobeNewswire)
May-06-25 05:55PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -18.70% -5.00%
10:00AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-05-25 09:47AM	Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? (Zacks)
May-02-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.05%
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha) +16.94%
Apr-15-25 04:04PM	Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity (Seeking Alpha) -7.09%
Apr-04-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -8.99%
Mar-19-25 04:31PM	Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? (InsiderMonkey) +5.17% -7.10%
Mar-07-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 01:04AM	Q4 2024 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 09:15AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-25-25 10:57AM	Taysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-19-25 08:00AM	Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 (GlobeNewswire)
Feb-07-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.42%
Jan-03-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-06-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-24 12:51PM	Q3 2024 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... (GuruFocus.com)
Nov-13-24 05:15PM	Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.53%
04:01PM	Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-24 08:00AM	Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13 (GlobeNewswire) +7.87%
Nov-01-24 04:30PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.47% -12.42%
Oct-22-24 08:00AM	Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress (GlobeNewswire)
Oct-16-24 03:42PM	Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey)
Oct-14-24 12:00PM	Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why (Zacks)
Oct-04-24 08:01AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-03-24 04:55AM	Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5? (Insider Monkey)
Sep-26-24 08:00AM	Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress (GlobeNewswire)
Sep-06-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 09:10AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:01AM	Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-24 08:00AM	Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12 (GlobeNewswire)
Aug-02-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-05-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-26-24 09:14AM	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -17.24%
08:36AM	Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today? (InvestorPlace)
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-25-24 06:34PM	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -7.33%
Jun-18-24 07:30AM	Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome (GlobeNewswire) -26.30%
07:02AM	Sanofi taps Belharra for immune drug research; AstraZenecas new cancer drug falls short (BioPharma Dive)
Jun-13-24 06:00AM	How to Invest in Penny Stocks in 2024: 3 Best Picks (InvestorPlace) +6.65%
Jun-12-24 07:00AM	Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting (GlobeNewswire)
Jun-07-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 04:31PM	Is Taysha Gene Therapies, Inc. (NASDAQ:TSHA) the Best Gene Therapy Company? (Insider Monkey) +5.54%
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-15-24 03:11AM	Taysha Gene Therapies Inc (TSHA) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com) +21.01%
May-14-24 08:57PM	TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +7.08%

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Emily McGinnis	Affiliate-Chief Pat. Adv. &	Feb 04 '26	Proposed Sale	4.72	901	4,253		Feb 04 06:44 PM
Fred Porter	Affiliate-Chief of Staff &	Feb 04 '26	Proposed Sale	4.72	889	4,196		Feb 04 06:42 PM
Sean McAuliffe	Affiliate - Chief Business Off	Feb 04 '26	Proposed Sale	4.72	914	4,314		Feb 04 06:41 PM
Rumana Haque-Ahmed	Officer	Feb 04 '26	Proposed Sale	4.72	697	3,290		Feb 04 06:39 PM
Kamran Alam	Officer	Feb 04 '26	Proposed Sale	4.72	1,655	7,812		Feb 04 06:38 PM
Nagendran Sukumar	President and Head of R&D	Jan 23 '26	Sale	4.75	89,132	423,377	1,344,307	Jan 27 04:05 PM
Nagendran Sukumar	President and Head of R&D	Jan 26 '26	Sale	4.61	26,918	124,092	1,317,389	Jan 27 04:05 PM
Nolan Sean P.	Chief Executive Officer	Jan 23 '26	Sale	4.75	136,789	649,748	2,949,569	Jan 27 04:05 PM
Nolan Sean P.	Chief Executive Officer	Jan 26 '26	Sale	4.61	41,312	190,448	2,908,257	Jan 27 04:05 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Jan 23 '26	Sale	4.75	78,968	375,098	1,467,635	Jan 27 04:05 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	4.61	23,849	109,944	1,443,786	Jan 27 04:05 PM
Sean P. Nolan	Officer	Jan 23 '26	Proposed Sale	5.09	168,078	855,517		Jan 23 08:07 PM
Sukumar Nagendran	Officer	Jan 23 '26	Proposed Sale	5.09	113,824	579,364		Jan 23 08:05 PM
Rumana Haque-Ahmed	Officer	Jan 23 '26	Proposed Sale	5.09	30,052	152,965		Jan 23 08:04 PM
Fred Porter	Affiliate-Chief of Staff &	Jan 23 '26	Proposed Sale	5.09	54,916	279,522		Jan 23 08:02 PM
Emily McGinnis	Affiliate-Chief Pat. Adv. &	Jan 23 '26	Proposed Sale	5.09	32,077	163,272		Jan 23 08:01 PM
Sean McAuliffe	Affiliate - Chief Business Off	Jan 23 '26	Proposed Sale	5.09	46,064	234,466		Jan 23 07:59 PM
Kamran Alam	Officer	Jan 23 '26	Proposed Sale	5.09	100,846	513,306		Jan 23 07:58 PM
Nagendran Sukumar	President and Head of R&D	Jan 12 '26	Option Exercise	1.15	200,000	229,440	1,206,439	Jan 14 04:45 PM
Nagendran Sukumar	President and Head of R&D	Jan 12 '26	Sale	4.71	200,000	942,000	1,006,439	Jan 14 04:45 PM
Nagendran Sukumar	Officer	Jan 12 '26	Proposed Sale	4.98	200,000	996,000		Jan 12 04:19 PM
Nagendran Sukumar	President and Head of R&D	Dec 01 '25	Option Exercise	1.71	260,047	444,680	1,266,486	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Nov 28 '25	Option Exercise	1.07	110,125	117,363	1,116,564	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Dec 01 '25	Sale	4.51	260,047	1,172,812	1,006,439	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Nov 28 '25	Sale	4.75	110,125	523,094	1,006,439	Dec 01 08:58 PM
Nagendran Sukumar	Officer	Nov 28 '25	Proposed Sale	4.86	370,172	1,799,036		Nov 28 01:07 PM
Rumana Haque-Ahmed	Officer	Sep 22 '25	Proposed Sale	2.83	10,770	30,479		Sep 22 07:18 PM
Nagendran Sukumar	President and Head of R&D	Sep 10 '25	Option Exercise	0.70	41,150	28,760	1,206,439	Sep 12 04:15 PM
Nagendran Sukumar	President and Head of R&D	Sep 10 '25	Sale	3.23	200,000	646,000	1,006,439	Sep 12 04:15 PM
Nagendran Sukumar	Officer	Sep 10 '25	Proposed Sale	3.26	200,000	652,000		Sep 10 04:28 PM
Nagendran Sukumar	President and Head of R&D	Aug 21 '25	Sale	2.85	57,054	162,604	1,165,289	Aug 22 04:15 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Aug 21 '25	Sale	2.85	54,491	155,299	1,187,603	Aug 22 04:15 PM
Kamran Alam	Officer	Aug 21 '25	Proposed Sale	2.87	54,491	156,389		Aug 21 09:12 PM
Emily McGinnis	Affiliate-Chief Pat. Adv. &	Aug 21 '25	Proposed Sale	2.87	19,604	56,263		Aug 21 09:11 PM
Sukumar Nagendran	Officer	Aug 21 '25	Proposed Sale	2.87	57,054	163,745		Aug 21 09:10 PM
Sean McAuliffe	Affiliate - Chief Business Off	Aug 21 '25	Proposed Sale	2.87	27,590	79,183		Aug 21 09:09 PM
Fred Porter	Affiliate-Chief of Staff &	Aug 21 '25	Proposed Sale	2.87	50,451	144,794		Aug 21 09:08 PM
Manning Paul B	10% Owner	May 30 '25	Buy	2.75	750,000	2,062,500	2,841,704	Jun 03 09:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TSHA

Taysha Gene Therapies Inc

Upgrade your FINVIZ experience